Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine

P C McHugh, G R Rogers, D M Glubb, P R Joyce, M A Kennedy

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Antidepressant drugs can exert significant effects on the mood of a patient suffering major depression and other disorders. These drugs generally have pharmacological actions on the uptake or metabolism of the neurotransmitters serotonin, noradrenaline and, to a lesser extent, dopamine. However, there are many aspects of antidepressant action we do not understand. We have applied proteomic analysis in a rat hippocampal model in an attempt to identify relevant molecules that operate in pathways functionally relevant to antidepressant action. Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis. After antidepressant exposure, we observed increased expression or modification of cytochrome c oxidase, subunit Va, cyclin-dependent kinase inhibitor 2A interacting protein, dynein, axonemal, heavy polypeptide 3 and RHO GDP-dissociation inhibitor alpha. Decreased expression or modification was observed for complexin 1 (CPLX1), alpha-synuclein, parvalbumin, ribosomal protein large P2, prohibitin, nerve growth factor, beta subunit (NGFB), peroxiredoxin 6 (PRDX6), 1-acylglycerol-3-phosphate O-acyltransferase 2_predicted, cystatin B (CYTB) and lysosomal membrane glycoprotein 1. CPLX1, the most strongly regulated protein observed, mediates the fusion of cellular transport vesicles with their target membranes and has been implicated in the pathophysiology of mood disorders, as well as antidepressant action. CPLX1 and the other proteins identified may represent links into molecular processes of importance to mood dysregulation and control, and their respective genes may represent novel candidates for studies of antidepressant pharmacogenetics.

LanguageEnglish
Pages1243-51
Number of pages9
JournalJournal of Psychopharmacology
Volume24
Issue number8
DOIs
Publication statusPublished - Aug 2010
Externally publishedYes

Fingerprint

Paroxetine
Proteomics
Antidepressive Agents
Hippocampus
1-Acylglycerol-3-Phosphate O-Acyltransferase
Axonemal Dyneins
Peroxiredoxin VI
Cystatin B
Proteins
Guanine Nucleotide Dissociation Inhibitors
Lysosome-Associated Membrane Glycoproteins
Cyclin-Dependent Kinase Inhibitor p16
Peroxiredoxins
Parvalbumins
Transport Vesicles
alpha-Synuclein
Electrophoresis, Gel, Two-Dimensional
Nerve Growth Factor
Electron Transport Complex IV
Mood Disorders

Cite this

McHugh, P C ; Rogers, G R ; Glubb, D M ; Joyce, P R ; Kennedy, M A. / Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. In: Journal of Psychopharmacology. 2010 ; Vol. 24, No. 8. pp. 1243-51.
@article{f36aa313faaf4fa7aa14461b9e227af8,
title = "Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine",
abstract = "Antidepressant drugs can exert significant effects on the mood of a patient suffering major depression and other disorders. These drugs generally have pharmacological actions on the uptake or metabolism of the neurotransmitters serotonin, noradrenaline and, to a lesser extent, dopamine. However, there are many aspects of antidepressant action we do not understand. We have applied proteomic analysis in a rat hippocampal model in an attempt to identify relevant molecules that operate in pathways functionally relevant to antidepressant action. Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis. After antidepressant exposure, we observed increased expression or modification of cytochrome c oxidase, subunit Va, cyclin-dependent kinase inhibitor 2A interacting protein, dynein, axonemal, heavy polypeptide 3 and RHO GDP-dissociation inhibitor alpha. Decreased expression or modification was observed for complexin 1 (CPLX1), alpha-synuclein, parvalbumin, ribosomal protein large P2, prohibitin, nerve growth factor, beta subunit (NGFB), peroxiredoxin 6 (PRDX6), 1-acylglycerol-3-phosphate O-acyltransferase 2_predicted, cystatin B (CYTB) and lysosomal membrane glycoprotein 1. CPLX1, the most strongly regulated protein observed, mediates the fusion of cellular transport vesicles with their target membranes and has been implicated in the pathophysiology of mood disorders, as well as antidepressant action. CPLX1 and the other proteins identified may represent links into molecular processes of importance to mood dysregulation and control, and their respective genes may represent novel candidates for studies of antidepressant pharmacogenetics.",
keywords = "Animals, Antidepressive Agents, Second-Generation/blood, Depression/drug therapy, Disease Models, Animal, Electrophoresis, Gel, Two-Dimensional, Hippocampus/drug effects, Image Processing, Computer-Assisted, Male, Paroxetine/blood, Proteins/metabolism, Proteomics, Rats, Rats, Sprague-Dawley",
author = "McHugh, {P C} and Rogers, {G R} and Glubb, {D M} and Joyce, {P R} and Kennedy, {M A}",
year = "2010",
month = "8",
doi = "10.1177/0269881109102786",
language = "English",
volume = "24",
pages = "1243--51",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "8",

}

Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. / McHugh, P C; Rogers, G R; Glubb, D M; Joyce, P R; Kennedy, M A.

In: Journal of Psychopharmacology, Vol. 24, No. 8, 08.2010, p. 1243-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine

AU - McHugh, P C

AU - Rogers, G R

AU - Glubb, D M

AU - Joyce, P R

AU - Kennedy, M A

PY - 2010/8

Y1 - 2010/8

N2 - Antidepressant drugs can exert significant effects on the mood of a patient suffering major depression and other disorders. These drugs generally have pharmacological actions on the uptake or metabolism of the neurotransmitters serotonin, noradrenaline and, to a lesser extent, dopamine. However, there are many aspects of antidepressant action we do not understand. We have applied proteomic analysis in a rat hippocampal model in an attempt to identify relevant molecules that operate in pathways functionally relevant to antidepressant action. Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis. After antidepressant exposure, we observed increased expression or modification of cytochrome c oxidase, subunit Va, cyclin-dependent kinase inhibitor 2A interacting protein, dynein, axonemal, heavy polypeptide 3 and RHO GDP-dissociation inhibitor alpha. Decreased expression or modification was observed for complexin 1 (CPLX1), alpha-synuclein, parvalbumin, ribosomal protein large P2, prohibitin, nerve growth factor, beta subunit (NGFB), peroxiredoxin 6 (PRDX6), 1-acylglycerol-3-phosphate O-acyltransferase 2_predicted, cystatin B (CYTB) and lysosomal membrane glycoprotein 1. CPLX1, the most strongly regulated protein observed, mediates the fusion of cellular transport vesicles with their target membranes and has been implicated in the pathophysiology of mood disorders, as well as antidepressant action. CPLX1 and the other proteins identified may represent links into molecular processes of importance to mood dysregulation and control, and their respective genes may represent novel candidates for studies of antidepressant pharmacogenetics.

AB - Antidepressant drugs can exert significant effects on the mood of a patient suffering major depression and other disorders. These drugs generally have pharmacological actions on the uptake or metabolism of the neurotransmitters serotonin, noradrenaline and, to a lesser extent, dopamine. However, there are many aspects of antidepressant action we do not understand. We have applied proteomic analysis in a rat hippocampal model in an attempt to identify relevant molecules that operate in pathways functionally relevant to antidepressant action. Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis. After antidepressant exposure, we observed increased expression or modification of cytochrome c oxidase, subunit Va, cyclin-dependent kinase inhibitor 2A interacting protein, dynein, axonemal, heavy polypeptide 3 and RHO GDP-dissociation inhibitor alpha. Decreased expression or modification was observed for complexin 1 (CPLX1), alpha-synuclein, parvalbumin, ribosomal protein large P2, prohibitin, nerve growth factor, beta subunit (NGFB), peroxiredoxin 6 (PRDX6), 1-acylglycerol-3-phosphate O-acyltransferase 2_predicted, cystatin B (CYTB) and lysosomal membrane glycoprotein 1. CPLX1, the most strongly regulated protein observed, mediates the fusion of cellular transport vesicles with their target membranes and has been implicated in the pathophysiology of mood disorders, as well as antidepressant action. CPLX1 and the other proteins identified may represent links into molecular processes of importance to mood dysregulation and control, and their respective genes may represent novel candidates for studies of antidepressant pharmacogenetics.

KW - Animals

KW - Antidepressive Agents, Second-Generation/blood

KW - Depression/drug therapy

KW - Disease Models, Animal

KW - Electrophoresis, Gel, Two-Dimensional

KW - Hippocampus/drug effects

KW - Image Processing, Computer-Assisted

KW - Male

KW - Paroxetine/blood

KW - Proteins/metabolism

KW - Proteomics

KW - Rats

KW - Rats, Sprague-Dawley

U2 - 10.1177/0269881109102786

DO - 10.1177/0269881109102786

M3 - Article

VL - 24

SP - 1243

EP - 1251

JO - Journal of Psychopharmacology

T2 - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 8

ER -